New Screen-to-Lead Data Analysis And Management Platform Genedata Screener(R) 5.5 Released

Main Category: Medical Devices
Article Date: 03 Apr 2008 - 16:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Genedata, a leading provider of in silico solutions for the pharmaceutical and life sciences industries, announced the release of Genedata Screener 5.5, its new enterprise solution for high throughput and high content screening analysis.

The Screener platform, currently in use at several large pharmaceutical and biotech companies, combines enterprise-wide assay data management with high-performance processing workflows and flexible analysis tools. Screener rapidly analyzes, integrates and manages all assay data, independent of instrumentation, technology, volume or location. The findings are then combined with chemical, pharmacological and in vivo data to support scientists in the tasks of compound prioritization and identification of quality lead structures with the highest confidence.

Screener 5.5 features easy integration of pharmacological fit models and advanced functionality for analyzing experiments with multiple readouts. Users will greatly benefit from the ability to integrate new fit models that are relevant for their particular workflows, such as the Morrison equation for Ki fitting, or new proprietary and public fit algorithms. In addition, the open and scalable architecture extends Screener's applicability as enterprise screening analysis platform, from uHTS centers to therapeutic areas, and provides access to a wide range of information in corporate research and drug discovery systems.

Dr. Othmar Pfannes, CEO of Genedata, said, "Already deployed worldwide throughout the pharmaceutical industry, Screener has been described as a catalyst in improving the quality of screening-based team research efforts in global enterprises. We are confident that our Screener 5.5 release will build on this excellent reputation, providing our growing customer base with the ways and means of mastering today`s screen-to-lead challenges."

Genedata specializes in software and professional services for pharmaceuticals, biotech and related life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data, Genedata Screener® for high throughput screening analysis, and Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and subsidiaries in Tokyo (Japan), Munich (Germany), Konstanz (Germany), Boston (USA) and San Francisco (USA).

http://www.genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Genedata